398 related articles for article (PubMed ID: 32722384)
1. The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines.
Helderman RFCPA; Löke DR; Verhoeff J; Rodermond HM; van Bochove GGW; Boon M; van Kesteren S; Garcia Vallejo JJ; Kok HP; Tanis PJ; Franken NAP; Crezee J; Oei AL
Cells; 2020 Jul; 9(8):. PubMed ID: 32722384
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Shimizu T; Sonoda H; Murata S; Takebayashi K; Ohta H; Miyake T; Mekata E; Shiomi H; Naka S; Tani T
Eur J Surg Oncol; 2014 May; 40(5):521-528. PubMed ID: 24388411
[TBL] [Abstract][Full Text] [Related]
3. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
4. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
[TBL] [Abstract][Full Text] [Related]
5. Elevated temperatures and longer durations improve the efficacy of oxaliplatin- and mitomycin C-based hyperthermic intraperitoneal chemotherapy in a confirmed rat model for peritoneal metastasis of colorectal cancer origin.
Helderman RFCPA; Bokan B; van Bochove GGW; Rodermond HM; Thijssen E; Marchal W; Torang A; Löke DR; Franken NAP; Kok HP; Tanis PJ; Crezee J; Oei AL
Front Oncol; 2023; 13():1122755. PubMed ID: 37007077
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
[TBL] [Abstract][Full Text] [Related]
7. Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Weber T; Roitman M; Link KH
Clin Colorectal Cancer; 2012 Sep; 11(3):167-76. PubMed ID: 22397952
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
[TBL] [Abstract][Full Text] [Related]
9. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
[TBL] [Abstract][Full Text] [Related]
10. Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Shannon NB; Chia CS; Soo KC; Teo MCC
Int J Hyperthermia; 2018 Aug; 34(5):595-600. PubMed ID: 28633580
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
Delhorme JB; Sauvinet G; Séverac F; Diab S; Liu D; Rohr S; Romain B; Brigand C
Ann Surg Oncol; 2022 Nov; 29(12):7568-7576. PubMed ID: 35882692
[TBL] [Abstract][Full Text] [Related]
12. 5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer.
Murata S; Yamamoto H; Shimizu T; Naitoh H; Yamaguchi T; Kaida S; Takebayashi K; Miyake T; Tani T; Tani M
J Surg Oncol; 2018 Mar; 117(4):671-677. PubMed ID: 29266509
[TBL] [Abstract][Full Text] [Related]
13. Effect of intraperitoneal chemotherapy concentration on morbidity and survival.
Elekonawo FMK; van Eden WJ; van der Plas WY; Ewalds RSG; de Jong LAW; Bremers AJA; Hemmer PHJ; Kok NFM; Kruijff S; Aalbers AGJ; de Reuver PR
BJS Open; 2020 Apr; 4(2):293-300. PubMed ID: 31950702
[TBL] [Abstract][Full Text] [Related]
14. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
Hulshof EC; Lurvink RJ; Caserta N; de Hingh IHJT; van Wezel T; Böhringer S; Swen JJ; Gelderblom H; Guchelaar HJ; Deenen MJ
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1925-1931. PubMed ID: 32354538
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO
Rotolo S; Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Pacelli F
Updates Surg; 2021 Aug; 73(4):1443-1448. PubMed ID: 33782856
[TBL] [Abstract][Full Text] [Related]
16. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
17. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
18. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Properties of Perfusate Fluid After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CS-HIPEC) with Mitomycin C.
Lange KN; McKay D; Gentry BG; Franko J
Ann Surg Oncol; 2017 Dec; 24(13):3837-3841. PubMed ID: 29019106
[TBL] [Abstract][Full Text] [Related]
20. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
Woeste MR; Philips P; Egger ME; Scoggins CR; McMasters KM; Martin RCG
J Surg Oncol; 2020 Jun; 121(8):1298-1305. PubMed ID: 32239529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
